Annals of Nuclear Medicine

, Volume 22, Issue 1, pp 83–86 | Cite as

Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma

  • Bishnuhari Paudyal
  • Noboru Oriuchi
  • Pramila Paudyal
  • Yoshito Tsushima
  • Tetsuya Higuchi
  • Mitsuyuki Miyakubo
  • Tomohiro Ishikita
  • Takashi Nakajima
  • Keigo Endo
Case Report

Abstract

We report the results of 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and immunohistochemical staining of glucose transporter 1 (Glut-1) and hexokinase II (HK-II) in patients with hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC) to observe the variation in 18F-FDG uptake and variation in expression of Glut-1 and HK-II in these hepatic tumors. In the case of HCC, moderate 18F-FDG uptake and strong expression of HK-II were detected, whereas Glut-1 was not expressed. Conversely, CCC showed high 18F-FDG uptake and increased expression of Glut-1 but HK-II was not expressed. The variation in the 18F-FDG uptake and expression of Glut 1 and HK-II in HCC and CCC might be owing to the difference in origin and the different mechanisms involved in glucose uptake, rate of glucose transporters, and hexokinase activity involved in the glycolytic pathway.

Keywords

18F-FDG PET Glucose transporter 1 Hexokinase II Hepatocellular carcinoma Cholangiocellular carcinoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bosch FX, Ribes J, Borras J, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9:191–211.PubMedCrossRefGoogle Scholar
  2. 2.
    Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006;45:43–50.PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004;8:90–97.PubMedCrossRefGoogle Scholar
  4. 4.
    Kim YJ, Yun M, Lee WJ, Kim KS, Lee JD. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2003;30:1467–1472.PubMedCrossRefGoogle Scholar
  5. 5.
    Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL. Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 2002;29:443–453.PubMedCrossRefGoogle Scholar
  6. 6.
    Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 2002;43:173–180.PubMedGoogle Scholar
  7. 7.
    Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, et al. [18F]FDG uptake and PCNA, Glut-1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005;7:369–379.PubMedCrossRefGoogle Scholar
  8. 8.
    Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 2003;97:1015–1024.PubMedCrossRefGoogle Scholar
  9. 9.
    Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, et al. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 2001;92:1144–1150.PubMedCrossRefGoogle Scholar
  10. 10.
    Kato H, Takita J, Miyazaki T, Nakajima M, Fukai Y, Masuda N, et al. Glut-1 glucose transporter expression in esophageal squamous cell carcinoma is associated with tumor aggressiveness. Anticancer Res 2002;22:2635–2639.PubMedGoogle Scholar
  11. 11.
    Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992;33:333–339.PubMedGoogle Scholar
  12. 12.
    Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811–1817.PubMedGoogle Scholar
  13. 13.
    Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32:792–797.PubMedCrossRefGoogle Scholar
  14. 14.
    Miyakubo M, Oriuchi N, Tsushima Y, Higuchi T, Koyama K, Arai K, et al. Diagnosis of maxillofacial tumor with L-3-[18F]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET. Ann Nucl Med 2007;21:129–135.PubMedCrossRefGoogle Scholar
  15. 15.
    Goel A, Mathupala SP, Pedersen PL. Glucose metabolism in cancer: evidence that demethylation events play a role in activating type II hexokinase gene expression. J Biol Chem 2003;278:15333–15340.PubMedCrossRefGoogle Scholar
  16. 16.
    Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996;56:1164–1167.PubMedGoogle Scholar
  17. 17.
    Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 1999;59:4709–4714.PubMedGoogle Scholar
  18. 18.
    Lee JD, Yang WI, Park YN, Kim KS, Choi JS, Yun M, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased 18F-FDG uptake. J Nucl Med 2005;46:1753–1759.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2008

Authors and Affiliations

  • Bishnuhari Paudyal
    • 1
  • Noboru Oriuchi
    • 1
  • Pramila Paudyal
    • 1
    • 2
  • Yoshito Tsushima
    • 1
  • Tetsuya Higuchi
    • 1
  • Mitsuyuki Miyakubo
    • 1
  • Tomohiro Ishikita
    • 1
  • Takashi Nakajima
    • 2
  • Keigo Endo
    • 1
  1. 1.Department of Diagnostic Radiology and Nuclear MedicineGunma University Graduate School of MedicineGunmaJapan
  2. 2.Nakajima Department of Tumor PathologyGunma University Graduate School of MedicineMaebashi, GunmaJapan

Personalised recommendations